Wiener klinische Wochenschrift

, Volume 124, Issue 3–4, pp 111–123 | Cite as

Primäre Immunthrombozytopenie des Erwachsenen – Diagnostik und Therapie, Konsensus-Statement der Österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO)

  • Ingrid Pabinger
  • Günther Gastl
  • Michael Steurer
  • Siegfried Sormann
  • Michael Fillitz
  • Josef Friedl
  • Dietmar Geissler
  • Klaus Geissler
  • Richard Greil
  • Paul Knöbl
  • Sibylle Kozek-Langenecker
  • Peter Krippl
  • Paul Kyrle
  • Alois Lang
  • Werner Linkesch
  • Heinz Ludwig
  • Markus Müller
  • Simon Panzer
  • Elisabeth Pittermann
  • Josef Thaler
  • Ansgar Weltermann
konsensusbericht

Zusammenfassung

Die Immunthrombozytopenie (ITP) ist eine seltene und bei den meisten Patienten nicht schwerwiegende Erkrankung, die jedoch auch zu schwerwiegenden oder sogar lebensbedrohlichen Blutungskomplikationen führen kann. Die Behandlung der ITP hat sich in den letzten Jahren durch neue therapeutische Optionen zum Teil verändert. Dem haben auch neue internationale Leitlinien Rechnung getragen. Das vorliegende Konsensusstatement der Österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO) hat nicht das Ziel, vorhandenes Wissen neu zu bewerten, sondern vielmehr die bereits publizierten internationalen Leitlinien für die Situation in Österreich zu diskutieren und zu adaptieren. Behandelt wird dabei nur die primäre ITP des Erwachsenen. Neben Klassifikation, Epidemiologie, Klinik und Diagnostik der primären ITP wird das Management der Erkrankung ausführlich diskutiert. Dabei wird auf aktuelle Aspekte von Therapien erster, zweiter und dritter Wahl, sowie die Splenektomie, deren Indikationen und mögliche Kontraindikationen und die Anwendung neuer Therapiemöglichkeiten, wie z.B. die Thrombopoetinrezeptor-Agonisten (TRA), eingegangen.

Schlüsselwörter

Primäre Immunthrombozytopenie Leitlinien Thrombopoetinrezeptor-Agonisten Splenektomie Eltrombopag Romiplostim 

Primary Immune Thrombocytopenia in Adults – Diagnostics and Treatment Consensus Statement of the Austrian Society of Hematology and Oncology (ÖGHO)

Summary

Immune Thrombocytopenia (ITP) is a rare and – in most patients – mild disease, but might be associated with severe or even life-threatening bleeding complications. The treatment of ITP has partly changed in recent years, due to new therapeutic options. International guidelines changed accordingly. This consensus statement by the Austrian Society of Hematology and Oncology (OEGHO) is not a new evaluation of the current evidence, but rather tries to discuss the available international guidelines and adapt them to the situation in Austria. The subject is primary ITP in adults only. Classification, epidemiology, clinical presentation and diagnostics of ITP, and especially the management of this disease, are discussed in detail. This includes current aspects of first, second, and third line therapies, splenectomy with its indications and contraindications, and the use of new therapeutic options like thrombopoetin receptor agonists (TRA).

Keywords

Primary immune thrombocytopenia Guidelines Adult patients Thrombopoetin receptor agonists Splenectomy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Matzdorff A, Giagounidis A, Greinacher A, Hiller E, Kiefel V, Muller-Beissenhirtz H, et al. Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH. Onkologie 2010;33(Suppl. 3):2–20PubMedCrossRefGoogle Scholar
  2. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86PubMedCrossRefGoogle Scholar
  3. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93PubMedCrossRefGoogle Scholar
  4. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–207PubMedCrossRefGoogle Scholar
  5. George JN. Diagnosis, clinical course, and management of idiopathic thrombocytopenic purpura. Curr Opin Hematol 1996;3:335–40PubMedCrossRefGoogle Scholar
  6. Kelton JG, Gibbons S. Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Semin Thromb Hemost 1982;8:83–104PubMedCrossRefGoogle Scholar
  7. Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–42PubMedCrossRefGoogle Scholar
  8. Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006;91:1041–5PubMedGoogle Scholar
  9. Simanek R, Panzer S, Lechner K, Pabinger I. Late spontaneous remissions in severe adult autoimmune thrombocytopenia. Ann Hematol 2007;86:705–10PubMedCrossRefGoogle Scholar
  10. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83:83–9PubMedCrossRefGoogle Scholar
  11. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711–2; author reply 713PubMedCrossRefGoogle Scholar
  12. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909–13PubMedGoogle Scholar
  13. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966–74PubMedCrossRefGoogle Scholar
  14. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377–83PubMedCrossRefGoogle Scholar
  15. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol 2009;145:235–44PubMedCrossRefGoogle Scholar
  16. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008PubMedCrossRefGoogle Scholar
  17. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123–4PubMedCrossRefGoogle Scholar
  18. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008;112:1078–84PubMedCrossRefGoogle Scholar
  19. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147–50PubMedCrossRefGoogle Scholar
  20. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325–8PubMedCrossRefGoogle Scholar
  21. Luley KB, Wagner T. Idiopathische thrombozytopenische Purpura (Morbus Werlhof) und ihre Abgrenzung von anderen thrombozytopenischen hämorrhagischen Diathesen. Med Klin 2009;104:372–85CrossRefGoogle Scholar
  22. McMillan R, Luiken GA, Levy R, Yelenosky R, Longmire RL. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978;239:2460–2PubMedCrossRefGoogle Scholar
  23. Alimardani G, Guichard J, Fichelson S, Cramer EM. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002;88:1039–46PubMedGoogle Scholar
  24. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887–95PubMedCrossRefGoogle Scholar
  25. Houwerzijl EJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500–6PubMedCrossRefGoogle Scholar
  26. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364–9PubMedCrossRefGoogle Scholar
  27. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33–40PubMedCrossRefGoogle Scholar
  28. Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999;106:430–4PubMedCrossRefGoogle Scholar
  29. Siegel RS, Rae JL, Barth S, Coleman RE, Reba RC, Kurlander R, et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989;30:206–12PubMedCrossRefGoogle Scholar
  30. Keine Autoren angegeben. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574–96Google Scholar
  31. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40PubMedGoogle Scholar
  32. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006;3:e24PubMedCrossRefGoogle Scholar
  33. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004;76:205–13PubMedCrossRefGoogle Scholar
  34. Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood 1997;89:1112–4PubMedGoogle Scholar
  35. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994;84:4203–8PubMedGoogle Scholar
  36. Anderson MJ, Peebles CL, McMillan R, Curd JG. Fluorescent antinuclear antibodies and anti-SS-A/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus. Ann Intern Med 1985;103:548–50PubMedGoogle Scholar
  37. Kurata Y, Miyagawa S, Kosugi S, Kashiwagi H, Honda S, Mizutani H, et al. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994;71:184–7PubMedGoogle Scholar
  38. Khellaf M, Quittet P, Viallard J-F, Alexis M, Cheze S, Durand J-M, et al. Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the "real-life": Result of the french experience in 72 adults. ASH Annual Meeting Abstracts, Blood 2009;114; Abstract #3519Google Scholar
  39. Soupir CP, Vergilio JA, Kelly E, Dal Cin P, Kuter D, Hasserjian RP. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol 2009;144:800–2PubMedCrossRefGoogle Scholar
  40. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113:1564–73PubMedCrossRefGoogle Scholar
  41. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–14PubMedCrossRefGoogle Scholar
  42. National Cancer Institute. NCI Common Terminology Criteria for Adverse Events: CTCAE, version MedDRA v9.0. [cited Jänner 2010]; Erhältlich unter: www.cancer.gov
  43. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54PubMedCrossRefGoogle Scholar
  44. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630–8PubMedCrossRefGoogle Scholar
  45. Bellucci S, Charpak Y, Chastang C, Tobelem G. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP) results of a randomized clinical trial in 160 children, 223 adults. Blood 1988;71:1165–9PubMedGoogle Scholar
  46. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994;331:1207–11PubMedCrossRefGoogle Scholar
  47. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the cooperative latin American group on hemostasis and thrombosis. Blood 1984;64:1179–83PubMedGoogle Scholar
  48. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504–22PubMedCrossRefGoogle Scholar
  49. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831–6PubMedCrossRefGoogle Scholar
  50. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755–62PubMedCrossRefGoogle Scholar
  51. Bae SH, Ryoo HM, Lee WS, Yoo YD, Lee KH, Lee JH, et al. High Dose Dexamethasone Vs. Conventional Dose Prednisolone for Adults with Immune Thrombocytopenia: A Prospective Multicenter Phase III Trial. ASH Annual Meeting. Orlando. Abstract #3687, 2010Google Scholar
  52. Clynes R. Immune complexes as therapy for autoimmunity. J Clin Invest 2005;115:25–7PubMedGoogle Scholar
  53. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83–6PubMedGoogle Scholar
  54. Ruggeri M, Castaman G, De Nardi G, Rodeghiero F. Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. Haematologica 1993;78:338–9PubMedGoogle Scholar
  55. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217–8PubMedCrossRefGoogle Scholar
  56. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256:339–42PubMedCrossRefGoogle Scholar
  57. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–700PubMedGoogle Scholar
  58. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28:249–55PubMedCrossRefGoogle Scholar
  59. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005;106:1532–7PubMedCrossRefGoogle Scholar
  60. Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost 2008;100:762–5PubMedGoogle Scholar
  61. Pamuk GE, Pamuk ON, Baslar Z, Ongoren S, Soysal T, Ferhanoglu B, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81:436–40PubMedCrossRefGoogle Scholar
  62. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068–71PubMedGoogle Scholar
  63. Nichol JL. Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells 1998;16(Suppl. 2):165–75PubMedCrossRefGoogle Scholar
  64. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–8PubMedCrossRefGoogle Scholar
  65. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE) a 6-month, randomised, phase 3 study. Lancet 2011;377:393–402PubMedCrossRefGoogle Scholar
  66. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008;371:395–403PubMedCrossRefGoogle Scholar
  67. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889–99PubMedCrossRefGoogle Scholar
  68. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161–71PubMedCrossRefGoogle Scholar
  69. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952–7PubMedCrossRefGoogle Scholar
  70. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002;69:95–100PubMedCrossRefGoogle Scholar
  71. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275–80PubMedCrossRefGoogle Scholar
  72. Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006;85:400–6PubMedCrossRefGoogle Scholar
  73. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999–1004PubMedCrossRefGoogle Scholar
  74. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25–33PubMedGoogle Scholar
  75. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695–8PubMedCrossRefGoogle Scholar
  76. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4–13PubMedGoogle Scholar
  77. Kaznelson P. Verschwinden der hämorrhagischen Diathese bei einem Falle von "essentieller Thrombopenie" (Frank) nach Milzexstirpation. Splenogene thrombolytische Purpura. Wien Klin Wochenschr 1916;29:1451–4Google Scholar
  78. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623–34PubMedCrossRefGoogle Scholar
  79. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 2010;89:1185–95PubMedCrossRefGoogle Scholar
  80. Winslow ER, Brunt LM. Perioperative outcomes of laparoscopic versus open splenectomy: A meta-analysis with an emphasis on complications. Surgery 2003;134:647–653; discussion 654–645PubMedCrossRefGoogle Scholar
  81. Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995;122:187–8PubMedGoogle Scholar
  82. Singer DB. Postsplenectomy sepsis. Perspect Pediatr Pathol 1973;1:285–311PubMedGoogle Scholar
  83. O'Neal BJ, McDonald JC. The risk of sepsis in the asplenic adult. Ann Surg 1981;194:775–8PubMedCrossRefGoogle Scholar
  84. Schwartz PE, Sterioff S, Mucha P, Melton LJ, 3rd, Offord KP. Postsplenectomy sepsis and mortality in adults. JAMA 1982;248:2279–83PubMedCrossRefGoogle Scholar
  85. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001;54:214–8PubMedCrossRefGoogle Scholar
  86. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Jacobsen J, Fryzek JP, et al. Risk for hospital contact with infection in patients with splenectomy: A population-based cohort study. Ann Intern Med 2009;151:546–55PubMedGoogle Scholar
  87. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861–8PubMedCrossRefGoogle Scholar
  88. Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ 2005;331:417–8PubMedCrossRefGoogle Scholar
  89. Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol 2008;83:93–6.PubMedCrossRefGoogle Scholar
  90. Wolters U, Wolf T, Stutzer H, Schroder T. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996;77:217–22PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ingrid Pabinger
    • 1
  • Günther Gastl
    • 2
  • Michael Steurer
    • 2
  • Siegfried Sormann
    • 3
  • Michael Fillitz
    • 4
  • Josef Friedl
    • 5
  • Dietmar Geissler
    • 6
  • Klaus Geissler
    • 7
  • Richard Greil
    • 8
  • Paul Knöbl
    • 1
  • Sibylle Kozek-Langenecker
    • 9
  • Peter Krippl
    • 10
  • Paul Kyrle
    • 1
  • Alois Lang
    • 11
  • Werner Linkesch
    • 3
  • Heinz Ludwig
    • 12
  • Markus Müller
    • 13
  • Simon Panzer
    • 14
  • Elisabeth Pittermann
    • 4
  • Josef Thaler
    • 15
  • Ansgar Weltermann
    • 16
  1. 1.Univ.-Klin. f. Innere Med. IMed. Univ. WienWienAustria
  2. 2.Univ.-Klin. f. Innere Med. VMed. Univ. InnsbruckInnsbruckAustria
  3. 3.Univ.-Klin. f. Innere Med.Med. Univ. GrazGrazAustria
  4. 4.3. Med. Abt., Hanusch-KHWienAustria
  5. 5.Univ.-Klin. f. ChirurgieMed. Univ. WienWienAustria
  6. 6.1. Med. Abt., LKH KlagenfurtKlagenfurtAustria
  7. 7.5. Med. Abt., KH HietzingWienAustria
  8. 8.Univ.-Klin. f. Innere Med. IIIParacelsus Med. Univ.SalzburgAustria
  9. 9.Abt. f. Anästhesie, Ev. KHWienAustria
  10. 10.Abt. f. Innere Med., KH FürstenfeldFürstenfeldAustria
  11. 11.Abt. f. Innere Med., LKH FeldkirchFeldkirchAustria
  12. 12.1. Med. Abt., WilhelminenspitalWienAustria
  13. 13.Univ.-Klin. f. Klin. PharmakologieMed. Univ. WienWienAustria
  14. 14.Univ.-Klin. f. Blutgruppenserologie u. TransfusionsmedizinMed. Univ. WienWienAustria
  15. 15.Abt. f. Innere Med. IV, Klinikum WelsWelsAustria
  16. 16.1. Interne Abt., KH d. ElisabethinenLinzAustria

Personalised recommendations